Cargando…
Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates
Second-generation COVID-19 vaccines could contribute to establish protective immunity against SARS-CoV-2 and its emerging variants. We developed COH04S1, a synthetic multiantigen modified vaccinia Ankara-based SARS-CoV-2 vaccine that co-expresses spike and nucleocapsid antigens. Here, we report COH0...
Autores principales: | Chiuppesi, Flavia, Nguyen, Vu H., Park, Yoonsuh, Contreras, Heidi, Karpinski, Veronica, Faircloth, Katelyn, Nguyen, Jenny, Kha, Mindy, Johnson, Daisy, Martinez, Joy, Iniguez, Angelina, Zhou, Qiao, Kaltcheva, Teodora, Frankel, Paul, Kar, Swagata, Sharma, Ankur, Andersen, Hanne, Lewis, Mark G., Shostak, Yuriy, Wussow, Felix, Diamond, Don J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8782996/ https://www.ncbi.nlm.nih.gov/pubmed/35064109 http://dx.doi.org/10.1038/s41541-022-00436-6 |
Ejemplares similares
-
Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants
por: Wussow, Felix, et al.
Publicado: (2023) -
COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants
por: Wussow, Felix, et al.
Publicado: (2022) -
Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial
por: Chiuppesi, Flavia, et al.
Publicado: (2022) -
Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy
por: Chiuppesi, Flavia, et al.
Publicado: (2023) -
Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform
por: Chiuppesi, Flavia, et al.
Publicado: (2020)